CYTOSORBENTS CORPORATION (NASDAQ:CTSO) Files An 8-K Other Events
Item 8.01
| Other Events. |
On May 5, 2017, CytoSorbents Corporation (the Company) announced
that positive results from the REFRESH (REduction in FREe
Hemoglobin) I trial were presented by the independent site
investigator at the American Association for Thoracic Surgery
(AATS) Centennial Conference in Boston, Massachusetts. The
Company previously announced in a press release dated March 27,
2017, that the REFRESH I trial abstract, submitted by study
investigators, had been selected for podium presentation at the
AATS Centennial Conference, with detail on the speaker, time and
place of the presentation.
The full text of the press release is filed as Exhibit 99.1 to
this Current Report on Form 8-K.
| Item 9.01 | Financial Statements and Exhibits. |
(d) Exhibits.
| Exhibit No. | Description. |
| 99.1 | Press Release of the Company dated May 5, 2017. |
About CYTOSORBENTS CORPORATION (NASDAQ:CTSO)
CytoSorbents Corporation is a critical care focused immunotherapy company. The Company is engaged in commercializing its product, CytoSorb, which is a blood purification technology with focus in preventing or treating multiple organ failure. The Company’s purification technologies are based on biocompatible, porous polymer beads that remove toxic substances from blood and other bodily fluids by pore capture and surface adsorption. The Company’s CytoSorb is an extracorporeal cytokine filter and is designed to reduce the cytokine storm that causes inflammation, organ failure and death in common critical illnesses, such as sepsis, burn injury, trauma, lung injury and pancreatitis. In addition, CytoSorb is used in other inflammatory conditions, such as cardiac surgery and autoimmune disease flares and cancer cachexia. It also has other products under development based upon its blood purification technology, including HemoDefend, ContrastSorb, DrugSorb, BetaSorb and others. CYTOSORBENTS CORPORATION (NASDAQ:CTSO) Recent Trading Information
CYTOSORBENTS CORPORATION (NASDAQ:CTSO) closed its last trading session down -0.15 at 4.70 with 205,304 shares trading hands.
